Eli Lilly reported second-quarter revenue of $23 billion, a 48% increase year over year, driven by soaring demand for its GLP-1 medications Mounjaro and Zepbound, according to the company’s earnings report. The pharmaceutical giant subsequently raised its annual revenue guidance to a range between $85 billion and $87 billion, pushing its stock price up nearly 5% by market close.
Eli Lilly Second-Quarter Revenue Jumps 48% on Mounjaro and Zepbound Sales
According to Eli Lilly’s financial disclosures, the primary catalysts for the company’s revenue growth are its flagship GLP-1 treatments. Mounjaro, prescribed for diabetes, generated $10 billion in second-quarter sales, representing a 91% increase compared to the same period last year. Meanwhile, Zepbound, marketed for obesity, brought in $5 billion, marking a 46% year-over-year jump. This financial momentum prompted leadership to lift full-year financial projections significantly.
Beyond current commercial products, the company outlined timelines for its pipeline. Retatrutide, a next-generation weight-loss drug, demonstrated substantial efficacy in clinical trials completed the prior month. Data showed that adults taking the medication lost an average of over 20% of their body weight after an 80-week treatment period. According to Eli Lilly, the company intends to submit an application for FDA approval of retatrutide in 2027.
Did you know? Eli Lilly’s market valuation surged following the earnings announcement as investors reacted to the expanding market for incretin-based therapies treating both type 2 diabetes and chronic weight management.
Cannabis-Derived Dronabinol Reduces PTSD Nightmares in Charité Study
Researchers at the German hospital Charité – Universitätsmedizin Berlin published a double-blind, placebo-controlled study in the journal Nature Medicine showing that a prescription medication made from THC directly derived from cannabis plants reduced nightmares in post-traumatic stress disorder patients. The ten-week trial evaluated 170 patients administered Dronabinol against a control group receiving a placebo, according to the published findings.
The study found that the nightmare burden among patients treated with Dronabinol decreased relative to the placebo cohort. Furthermore, five out of six patients in the treatment group reported that their overall health was markedly improved. Data specifically indicated that at least 21% of patients taking the cannabis-derived drug experienced a 50% reduction in nightmares, while over one-third reported the complete cessation of nightmares after the ten-week medication period.
Apnimed Raises $192 Million in IPO to Fund Sleep Apnea Treatment
Massachusetts-based Apnimed completed an initial public offering, raising $192 million as its shares began trading on the public market, according to corporate announcements. The company is developing a pharmacological treatment for sleep apnea, a condition that impacts up to 80 million Americans. Apnimed has already submitted its drug candidate to the FDA for review, with a potential regulatory decision expected in the first quarter of 2027.
Market response to the offering was strong. Shares were initially priced at $16 ahead of the Friday opening, but quickly climbed to open at $22. By Wednesday’s market close, the stock finished the trading session at $26.51. The capital injection provides the clinical-stage pharmaceutical company with resources to advance its pipeline toward commercialization.
Global Health Updates: WHO Estimates Undercounted Ebola and Dormant Viruses Waking Up
Public health authorities tracking infectious diseases released several surveillance updates regarding outbreaks and viral mechanisms. The World Health Organization estimated that the ongoing Ebola outbreak in Congo has likely infected three to four times more individuals than reflected in official case counts. In domestic surveillance, health agencies added six new states—Arkansas, Iowa, Nebraska, New Hampshire, North Carolina, and Missouri—to the ongoing multi-state cyclosporiasis outbreak.
In virology research, a large-scale study confirmed that Covid-19 infections can reactivate dormant viruses already present in the human body, potentially triggering secondary illnesses. Concurrently, in the pharmaceutical sector, AstraZeneca and CSPC Pharmaceutical announced plans to establish a joint venture based in China dedicated to biologics manufacturing, expanding cross-border production capabilities.
Frequently Asked Questions
What drove Eli Lilly’s revenue increase in the second quarter?
Eli Lilly’s 48% revenue increase to $23 billion was primarily driven by massive sales gains from its GLP-1 receptor agonists, specifically Mounjaro, which grew 91% to $10 billion, and Zepbound, which grew 46% to $5 billion.
When does Eli Lilly plan to seek FDA approval for retatrutide?
According to the company’s earnings disclosures, Eli Lilly plans to submit retatrutide for FDA approval in 2027, following clinical trial results showing average weight loss exceeding 20% after 80 weeks.
How much did Apnimed raise in its initial public offering?
Apnimed raised $192 million in its IPO, with shares opening at $22 after being priced at $16, and eventually closing at $26.51.
What did the Charité study discover about cannabis-derived drugs for PTSD?
Researchers found that Dronabinol, a THC-derived prescription medication, reduced the nightmare burden in PTSD patients over a ten-week period, with over a third of participants reporting no further nightmares.
To get updates on biotech IPOs, clinical trial results, and pharmaceutical earnings delivered directly to your inbox, subscribe to our weekly briefings.
Worth a look